The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company's (NYSE: LLY) investigational antibody therapy for Alzheimer's disease (AD).
Donanemab, an investigational antibody developed by Eli Lilly, has demonstrated positive results in a phase IIa trial in patients with early-stage Alzheimer’s disease (AD).